Pharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the U.S. in the month of September:

Pharming Group N.V. announces it will hold an Extraordinary General Meeting of Shareholders (EGM) on Monday, September 25, 2023 at 14:00 CEST.

Single-arm Phase III study in Japan evaluating leniolisib in patients aged 12 years and older with APDS, a rare primary immunodeficiency

Pharming Group N.V. presents its preliminary (unaudited) financial report for the second quarter and first half ended June 30, 2023.

Pharming Group N.V. announces today that the Board of Directors has nominated Dr. Richard Peters to become Pharming’s new Chairman.

Pharming Group N.V. confirms it will report its preliminary (unaudited) second quarter and first half 2023 financial results, for the period ended June 30, on Thursday, August 3, 2023.

Pharming is delighted to announce that CEO Sijmen de Vries was the winner of the Chief Executive of the Year Award at the 2023 European Mediscience Awards in London on Thursday evening. Scroll down for the Dutch translation.

Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it has entered into a definitive agreement with Novartis Pharma A.G. (“Novartis") to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to Novartis for a pre-agreed, one-time payment of approximately US$21.1 million shortly after closing.

Pharming Group N.V. announces that Pharming’s management will attend the following investor conferences in the month of June:

Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, the proposal for a specific authorization for the issuance of shares (or rights to acquire shares) to finance mergers, acquisitions, or strategic alliances, was not put up for a vote. All other proposals were approved.